anorexia/headache

Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China.

This observational study is aimed to provide additional safety and effectiveness data for Ergoferon in the treatment of influenza/acute viral URI in adult and pediatric outpatients, including cases with delayed treatment initiation (after 48 or 72 h of the onset of illness), and in allergy patients.

Coronavirus Disease 2019 (COVID-19) is a highly contagious disease, caused by a novel enveloped RNA beta-coronavirus, also known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The first case of this unprecedented outbreak "pneumonia of unknown etiology" was reported in Wuhan City,

Humanity has been experiencing a new pandemic of the SARS Coronavirus-19 virus (SARS-CoV-2) since December 2019, causing the disease known as COVID-19. As of March 23, 2020, there have been 382,341 documented episodes of infection worldwide, of which 16,567 have died. An important limitation in the

The exact prevalence of COVID-19 is unknown. Due to the relatively high number of diagnosed, symptomatic infections despite a strict policy, we expect a high prevalence of COVID 19 throughout the entire population. The risk that an asymptomatic carrier who is admitted to the hospital for a

research design: A randomized controlled trial was designed. According to the established inclusion criteria/exclusion criteria, the subjects were randomly divided into two groups by random number table. Each group received Mesenchymal Stem Cells(MSCs)from fat sources and conventional diabetic foot

Acute mountain sickness (AMS) is a constellation of symptoms including headache, sleep disturbance, fatigue, dizziness, and nausea, vomiting, or anorexia that commonly occurs in travelers ascending to altitudes above 2,500m. AMS incidence varies based on altitude and ascent profile with rates

Prior to surgery, all patients will undergo pre-anesthetic checkup including detailed history, physical, systemic examination, height and weight of the patient. All patients will be investigated for exclusion of any of the above mentioned contraindications. Routine preoperative laboratory

The goal of this study is to establish the effect of the compensation of vitamin D deficiency in the treatment of drug-resistant epilepsy with a high level of evidence in a large population. For that, the investigator aim to perform a controlled multicentre prospective double-blind randomized study

Breast reconstruction (BR) is commonly requested following mastectomy, and recent measures have been taken to ensure patient access is universal. Transferring autologous tissue from the abdomen using microvascular surgical techniques provides a reliable reconstruction method with high levels of

The vaccine being tested in this study is Takeda's Tetravalent Dengue Vaccine Candidate (TDV). TDV is being tested to protect people against dengue fever and to look at long-term safety results. This study will look at the success rate of TDV in preventing dengue fever (vaccine efficacy) and

Alzheimer's disease (AD) is a progressive type of dementia that causes problems with memory, thinking and behavior that gradually worsen over time. With an aging population, AD is an escalating problem, currently affecting an estimated 35 million people worldwide, with this number expected to grow

Ribavirin (RBV) is a synthetic guanosine analogue that is used to treat patients infected with hepatitis C virus (HCV). For many years, RBV has been the cornerstone of the HCV treatment in combination with peg interferon (PEG-IFN). Since the development of direct-acting antivirals (DAA), PEG-IFN

1. Primary immunogenicity endpoint - Geometric Mean Titer (GMT) of Vibriocidal antibodies against Inaba serogroup O1 post second dose - GMTof Vibriocidal antibodies against Ogawa serogroup O1 post second dose - GMT of Vibriocidal antibodies against serogroup O139 post second dose 2. Secondary

The epidemiology and transmission dynamics of influenza in hospitals are only poorly understood, particularly with respect to subjects without symptoms of influenza infection (e.g. without fever, cough, sore throat, nasal congestion, weakness, headache, loss of appetite, or myalgia). Knowledge about